Tonsil lymphoma
Conditions
Interventions
Case group:None
Control group:None
Sponsors
Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Lymphoma patients: (1) Patients who underwent tonsil operation or biopsy and were pathologically diagnosed as lymphoma. (2) Patients who read the informed consent form (approved by the ethics Committee of the hospital), voluntarily participate in the project and sign it. 2. Control: (1) Tonsil operation or biopsy, pathological diagnosis of chronic tonsillitis or other non-neoplastic diseases. (2) Subjects who read the informed consent form (approved by the ethics Committee of the hospital), voluntarily participate in the project and sign it.
Exclusion criteria
Exclusion criteria: 1. Previously receiving radiotherapy, chemotherapy, surgery or molecular targeted therapy less than 3 weeks after completion of treatment; 2. Patients had an active infection (requiring antibacterial, viral, or fungal drugs), or unexplained fever >38.5? that occurred during screening and occurred within one week prior to initial administration (the investigator determined that patients could be enrolled if their fever was due to tumor); Have received any form of organ transplantation, including allostem cell transplantation; 3. Patients with poorly controlled cardiac clinical symptoms or diseases, such as NYHA grade 2 or above heart failure, unstable angina pectoris, myocardial infarction within 1 year, clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention, and left ventricular ejection fraction =1000IU/ml or copy number positive as measured by the study center; Hepatitis C (hepatitis C antibody positive and HCV-RNA higher than the assay limit); 8. Received live vaccine within 4 weeks prior to screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD20;CD79a;PAX-5;Cyclin D1;CD10;CD21;CD5;B-cell lymphoma-2 (BCL-2);B-cell lymphoma-6 (BCL-6);C-myc;Ki67;MUM1;C-MYC translocation;BCL-2 translocation;Interferon regulatory factor 4 translocation;BCL-6 translocation; | — |
Countries
China
Contacts
Public ContactChen Nijun
Outcome results
None listed